Twist Bioscience Corporation

DB:0ME Stock Report

Market Cap: €2.5b

Twist Bioscience Management

Management criteria checks 3/4

Twist Bioscience's CEO is Emily Leproust, appointed in Apr 2013, has a tenure of 11.75 years. total yearly compensation is $7.62M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.48% of the company’s shares, worth €12.58M. The average tenure of the management team and the board of directors is 2.8 years and 8.2 years respectively.

Key information

Emily Leproust

Chief executive officer

US$7.6m

Total compensation

CEO salary percentage9.0%
CEO tenure11.8yrs
CEO ownership0.5%
Management average tenure2.8yrs
Board average tenure8.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Emily Leproust's remuneration changed compared to Twist Bioscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024US$8mUS$685k

-US$209m

Jun 30 2024n/an/a

-US$220m

Mar 31 2024n/an/a

-US$192m

Dec 31 2023n/an/a

-US$206m

Sep 30 2023US$8mUS$685k

-US$205m

Jun 30 2023n/an/a

-US$209m

Mar 31 2023n/an/a

-US$213m

Dec 31 2022n/an/a

-US$214m

Sep 30 2022US$6mUS$665k

-US$218m

Jun 30 2022n/an/a

-US$208m

Mar 31 2022n/an/a

-US$188m

Dec 31 2021n/an/a

-US$165m

Sep 30 2021US$1mUS$590k

-US$152m

Jun 30 2021n/an/a

-US$135m

Mar 31 2021n/an/a

-US$123m

Dec 31 2020n/an/a

-US$117m

Sep 30 2020US$7mUS$519k

-US$140m

Jun 30 2020n/an/a

-US$147m

Mar 31 2020n/an/a

-US$147m

Dec 31 2019n/an/a

-US$141m

Sep 30 2019US$8mUS$477k

-US$108m

Jun 30 2019n/an/a

-US$96m

Mar 31 2019n/an/a

-US$86m

Dec 31 2018n/an/a

-US$77m

Sep 30 2018US$525kUS$362k

-US$71m

Compensation vs Market: Emily's total compensation ($USD7.62M) is above average for companies of similar size in the German market ($USD2.04M).

Compensation vs Earnings: Emily's compensation has been consistent with company performance over the past year.

CEO

Emily Leproust (50 yo)

11.8yrs

Tenure

US$7,620,611

Compensation

Dr. Emily Marine Leproust, Ph.D. serves as Independent Director at CM Life Sciences, Inc. since September 2, 2020. She serves as an Independent Director at GeneDx Holdings Corp. (formerly known as Sema4 Ho...

Leadership Team

NamePositionTenureCompensationOwnership
Emily Leproust
Co-Founder11.8yrsUS$7.62m0.48%
€ 12.2m
Patrick Finn
President & COO2.3yrsUS$3.85m0.13%
€ 3.3m
Adam Laponis
Chief Financial Officerless than a yearUS$5.01m0.012%
€ 294.5k
Dennis Cho
Senior VP3.3yrsUS$1.80m0.070%
€ 1.8m
Paula Green
Senior Vice President of Human Resources8.8yrsUS$2.01m0.063%
€ 1.6m
William Banyai
Senior VP of Advanced Development5yrsUS$2.33m0.50%
€ 12.7m
Robert Werner
VP & Chief Accounting Officer1.7yrsno data0.018%
€ 454.7k
Siyuan Chen
Chief Technology Officer3.9yrsno datano data
Michael Fero
Chief Information Officerless than a yearno datano data
Nicole Moreno
Senior Vice President of Sales & Supportless than a yearno datano data
Angela Bitting
Chief ESG Officer & Senior VP of Corporate Affairs3.9yrsno datano data
Mark Buck
Senior Vice President of Operations1.3yrsno datano data

2.8yrs

Average Tenure

52yo

Average Age

Experienced Management: 0ME's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Emily Leproust
Co-Founder11.8yrsUS$7.62m0.48%
€ 12.2m
William Banyai
Senior VP of Advanced Development11.8yrsUS$2.33m0.50%
€ 12.7m
Keith Crandell
Independent Director11.3yrsUS$272.48k0.15%
€ 3.8m
Robert Chess
Lead Independent Director10.5yrsUS$307.48k0.027%
€ 673.5k
Nelson Chan
Independent Director5.7yrsUS$284.99k0.030%
€ 756.6k
Robert Ragusa
Independent Director8.2yrsUS$277.48k0.022%
€ 558.3k
Jan Johannessen
Independent Director6.3yrsUS$284.98k0.014%
€ 345.8k
Melissa Starovasnik
Independent Director3.4yrsUS$277.48k0.019%
€ 482.5k
Xiaoying Mai
Independent Director6.5yrsUS$269.98k0.043%
€ 1.1m

8.2yrs

Average Tenure

64yo

Average Age

Experienced Board: 0ME's board of directors are considered experienced (8.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/12 01:43
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Twist Bioscience Corporation is covered by 16 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Gaurav GoparajuBerenberg